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1. Introduction 
Alpha one antitrypsin protein (A1AT), is encoded on the SERPINA1 (serpin peptidase 
inhibitor, claude A, member 1 gene), (OMIM 107400), located on chromosome 14q32.1 and 
functions as inhibitor of the enzyme neutrophil elastase. People with a low serum level of 
this protein are described as having the alpha-1-antrypsin deficiency (A1ATD), (OMIM 
#613490), one of the most common heritable disorders. Having this disorder can predispose 
an individual to a variety of clinical diseases, with the lungs and the liver being the two 
organs most commonly affected. The A1AT protein is synthesized mainly in the liver by 
hepatocytes, secreted into the blood stream, and acts as an inhibitor of neutrophil elastase 
released primarily in the lung during inflammation. The most common allele for the 
SERPINA1 gene is named M (Middle), which encodes a normal A1AT protein identified in 
the middle on an isoelectric focusing gel. Over 120 allelic variants have been discovered and 
are named based on their position and movement on isoelectric gels, A-L if they exhibit 
faster migration than M, and N-Z if the proteins migrate more slowly. Rare mutations are 
often named after the discoverer or location of discover (Mmalton, Lowell, etc).  A patient's 
genotype is notated as PI*Allele-Allele, and so patient homozygous for the wild-type A1AT 
protein is noted as being PI*M-M.  
The most common allelic variation causing clinical disease is the Z protein, manifesting 
most often in the setting of the genotype PI*Z-Z. This mutated protein spontaneously 
misfolds and then polymerizes with other misfolded A1AT proteins, becoming trapped in 
large quantities in the endoplasmic reticulum of liver hepatocytes. This results in liver 
inflammation and fibrosis, and can lead to clinically significant cholestasis and cirrhosis. Not 
all allelic variants of A1ATD cause liver damage, however, as some encode truncated 
proteins which do not misfold or polymerize. Rare null mutations have also been discovered 
due to point mutations that introduce a premature stop codon within the DNA sequence. 
Patients with the genotype PI*Null-Null do not develop liver disease because they do not 
synthesize mutated protein, but are at extremely high risk for the development of lung 
disease because of their inability to inhibit neutrophil elastase. 
In the case of the Z allele, the trapped protein is ineffectively secreted into the blood stream, 
resulting in a low serum concentration of A1AT. The mutated protein also has a reduced 
functional activity, making it a less effective inhibitor of neutrophil elastase. Without an 
appropriate level of functional A1AT in lung tissue, neutrophil elastase is free to break 
down elastin, a critical component of lung structure, which is thought to be the major 
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mechanism leading to lung damage and the development of emphysema. The lung injury is 
worsened in the setting of chronic tobacco use, making smoking cessation paramount in the 
management of people with the deficiency.  
Clinical disease associated with the A1AT deficiency is highly variable, suggesting that many 
genetic modifiers and environmental exposures play a role in the disease expression. The 
typical symptoms of pulmonary disease include exertional shortness of breath, wheezing, and 
chronic cough. The cornerstone of disease management is ensuring total smoking abstinence 
in all patients, as smoking is associated with a much higher rate of decline in lung function in 
patients with A1AT deficiency. Replacement therapy with purified A1AT protein given 
intravenously has been approved in several countries as treatment of the deficiency state, and 
can prevent decline in lung function. Though many studies support its use and clinical benefit, 
true randomized placebo controlled studies have been limited in size and scope. 
2. History of the disorder 
In 1962 at the University of Lund, Sweden, Dr. Carl-Bertil Laurell (1919-2001) was 
examining the serum protein electrophoresis strips of patients with chronic obstructive 
pulmonary disease, when he noted an absence of the alpha-one band in a small group of 
patients. Dr. Sten Eriksson was a resident at the University hospital at the time and assisted 
Laurell in the study because of his previous experience with protein chemistry. Together, 
they discovered five cases that formed the basis of their first report of alpha one- antitrypsin 
deficiency. Three of the five patients in their report developed emphysema at an early age, 
leading to the conclusion that there must be an association between pulmonary disease and 
the alpha-one band deficiency (Laurell & Eriksson 1963). 
It was later discovered that the major function of the alpha 1-antitrypsin protein was to 
inhibit the enzyme neutrophil elastase, a protease released by neutrophils in the lungs 
during inflammation. Neutrophil elastase was shown to induce experimental emphysema in 
animals. (Senior, et al. 1977). These findings lead to the first hypothesis describing the 
pathogenesis of lung disease, that an imbalance of proteases and anti-proteases could result 
in an unregulated destruction of critical components of lung structure, namely elastin, 
leading to the development of clinical lung disease. This hypothesis continues to be central 
to the understanding of lung disease pathogenesis to this day, and helps explain why 
patient deficient in A1AT, which could not regulate neutrophil elastase, would be 
predisposed to emphysema development. 
Work by Dr. H. L. Sharp described the association between alpha one antitrypsin deficiency 
and liver disease in 10 children in 1969 (Sharp et al., 1969). Sharp discovered intracellular 
inclusions in the liver hepatocytes of A1ATD individuals, and further work found these 
inclusions to be polymers of the mutant Z allele of the A1AT protein. Evidence for A1ATD 
was also supported from the results of a large epidemiologic study published in 1976 by 
Sveger in Sweden (Sveger, 1976). After screening 200,000 infants for A1ATD he identified 
127 infants and found that 14 developed cholestatic jaundice in infancy. These studies 
established the role of A1AT in liver disease pathogenesis. 
3. Genetics 
Alpha-1-antitrypsin deficiency has been described as an autosomal co-dominant disorder or 
as an autosomal recessive disorder. Patients who are heterozygote for the enzyme deficiency 
have roughly half the serum concentration of A1AT compared with normal individuals, and 
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homozygote have a very low serum concentration of enzyme. This pattern of enzyme levels 
has lead many authors to describe the inheritance pattern as autosomal co-dominant, (see 
DeMeo’s review on the genetics of A1ATD as one example (DeMeo & Silverman, 2004)). 
Heterozygotes have only a small increased risk for developing clinically significant disease, 
while homozygotes are at a much higher risk for developing disease, leading other authors 
to describe the deficiency as having autosomal recessive inheritance (see Alpha-1 antitrypsin 
deficiency page on the National Center for Biotechnology Information website as an 
example). We prefer to describe the inheritance pattern as autosomal co-dominant, as this 
highlights the fact that heterozygotes for the deficiency are at an increased risk for clinical 
disease when compared with the general population, especially in the setting of external risk 
factors for lung disease (e.g. smoking). Another important characteristic of the deficiency is 
its variable clinical expressivity. Some homozygotes for the deficiency do not develop 
impairment in the lung function and never develop symptoms related to the disease 
(Seersholm & Kok-Jensen 1998). Incomplete penetrance and variable clinical phenotype 
(expressivity) is one of the reasons why population studies estimating the number of 
individuals with the deficiency are much higher than the actual number of people who have 
been diagnosed. For unclear reasons, A1ATD is rarely tested for despite guidelines that 
recommend otherwise for clear patient types. Complicating A1ATD diagnosis is the 
continued low rate of diagnosis and management of Chronic Obstructive Pulmonary 
Disease (COPD). 
More than 120 mutations in the SERPINA1 gene have been identified, although many do not 
cause a defect in the serum protein or function or relevant clinical disease (US National 
Library of Medicine August 2009). The allele most common to the general population is the 
M allele, and the most clinically relevant variants are the S and Z alleles. People with the 
PI*Z-Z genotype make up at least 95% of deficient individuals who present with clinical 
disease, and PI*M-Z heterozygotes on very rare occasion have any symptoms. The Z allele is 
caused by a glutamic acid to lysine substitution at position 342. A more common allelic 
variant is the S protein, caused by a glutamic acid to valine substitution at position 264. This 
protein is successfully degraded before accumulating in the liver and does not cause liver 
disease. PI*S-S individuals are not thought to be at risk for pulmonary disease, however the 
compound heterozygotes PI*S-Z or PI*S-null are at an increased risk for developing 
pulmonary symptoms. Null alleles are due to mutations that introduce an early stop codon, 
which prevents complete transcription of the gene. Patients who are homozygote for the 
null mutation (PI*null-null), or heterozygote with Z (PI*null-Z) are at the highest risk for 
developing severe pulmonary symptoms (Stoller & Aboussouan, 2005). 
The Z allele occurs mainly within one haplotype, meaning that other genetic material 
surrounding the allele is similar, and suggests a single relatively recent origin in Caucasians 
(Cox et al., 1985). Its high frequency in southern Scandinavia and estimated origination date 
of approximately 2000 years ago suggests that the mutation originated in the Viking 
population and was spread across Europe by Viking raiders. Using the pooled 
epidemiological data on 75,390 individuals, researchers estimated the prevalence of both the 
Z and S mutation in 21 countries. With this information, they created a topographic map of 
the mutation prevalence, depicting how the mutation may have spread. The ZZ phenotype 
shows highest prevalence in the southern Scandinavian Peninsula, Latvia, and Denmark, 
and progressively decreases towards the South and the East of Europe. The S allele has its 
highest prevalence in the Iberian Peninsula, which includes modern day Portugal, and 
Spain, as well as Southern France and gradually decreases towards the North, South and 
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East of the continent. The S mutation appears to have originated within the Portuguese 
population, but its date of origin is unknown. It is assumed that both mutations were 
introduced to North America by mass migration. 
 
 
Fig. 1. Common alleles of the SERPINA1 gene (adapted from Hogarth & Rachelefsky, 2008) 
4. Epidemiology 
There is an estimated 1.1 million people with severe A1ATD and 116 million carriers in the 
world (Luisetti & Seersholm, 2004). Although previously consider a disease of Caucasians, 
recent data shows that A1ATD exists in all racial subgroups worldwide including African 
blacks, Arabs and Jews in the Middle East, as well as people from central, far east and south 
east Asia (de Serres, 2002). Determining the number of people in the United States with 
emphysema primarily due to A1ATD can made by taking the estimate of the number of 
Americans with COPD (3.1 million), and the estimate that about 1.9% of patients with 
emphysema are likely due to A1ATD (Lieberman et al., 1986). This results in an estimate 
that at least 59000 individuals in the United States have severe symptomatic COPD due to 
A1ATD. Large screening studies have also been undertaken, including the classic 
prevalence study done by Sveger, where 200,000 neonates were screened at birth in Sweden 
(Sveger 1974). The results demonstrated 1 in 1575 live births were homozygous for the Z 
mutation (PI*ZZ). A similar study undertaken in Oregon, USA screened 107,038 newborns 
and found the prevalence of the ZZ phenotype in that population to be 1 in 5097 (O’Brien et 
al., 1978). Among 20,000 healthy blood donors tested in St. Louis, Missouri in the United 
States, 1 in 2857 were homozygous for the Z mutation. With this information, the 
researchers estimated a total prevalence of 700 individuals in St. Louis with the deficiency, 
however they were only to locate 28 (4%) after contacting local doctors (Silverman, et al., 
1989). Estimates from Central and Southern Africa based on limited data from screening 
studies estimated that 1 in 15 Africans are S carriers. Our own data on carrier rate in 
Americans of African Descent demonstrate 1 in 18 are S carriers. Epidemiologic data not 
only highlight that prevalence of the deficiency is high, but reinforce that the disease is 
significantly under diagnosed in most populations. 
5. Pathophysiology 
The SERPINA1 gene, previously known as the PI (proteasome inhibitor) gene, is located 
between 14q31.1-32.3 on the human genome, and encodes A1AT, which is a 52-kD 
glycoprotein composed of 394 amino acids. The active site is a single peptide bond, Met358-
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Ser359. The protein is primarily synthesized and secreted by hepatocytes, but also in 
mononuclear cells, intestinal and lung epithelial cells. A1AT is an acute phase reactant with 
a normal concentration in serum of 20-53 micromole/L. Alpha one antitrypsin is a member 
of the serpin family of protease inhibitors, which regulate important proteolytic enzyme 
cascades including the coagulation cascade, complement cascade, and plasmin inhibition 
(Crowther et al., 2004). Serpins not only inhibit proteases but cause a conformational change 
in their structure readying them for destruction. A1AT’s mechanism of inhibition has been 
likened to a mouse-trap. When neutrophil elastase attacks A1AT enzyme, it binds and then 
cleaves its reactive center loop, which causes a spring-like movement within the A1AT 
molecule to fling the elastase molecule across itself, inhibiting its function and altering its 
structure so it can be destroyed (Huntington et al., 2000). 
5.1 Pulmonary pathophysiology 
The prevailing theory describing the pathogenesis of emphysema in A1AT deficient 
individuals is of an imbalance in protease and anti-protease enzymes in lung tissue. 
Neutrophil elastase is released during inflammation and leads to an uncontrolled 
proteolytic attack on elastin, which is left unchecked by the low concentration of alpha one 
antitrypsin (Gadek et al., 1981). Furthermore, the circulating Z allele of A1AT has been 
shown to have a less functional active site, making the small amount of mutant protein a 
functionally ineffective inhibitor of neutrophil elastase (Ogushi et al., 1987). Elastin is the 
backbone of lung structure, and a critical component of the lungs ability to recoil. It is 
thought that elastin’s destruction leads to lung hyperinflation and obstruction, leading to 
development of emphysema.  
More recently, studies have shown that the mutated protein can form polymers within the 
lungs, similar to the polymerization occurring in the liver, and become chemoattractants for 
neutrophils resulting in excessive inflammation. Polymers of the mutated A1AT protein 
have been identified in the bronchial alveolar lavage fluid of individuals with the PiZZ 
phenotype (Mulgrew et al., 2004). These findings have lead to a possible evolutionary 
explanation for why alpha-one anti-trypsin deficiency became so prevalent in many 
populations. The argument for the selective advantage of being a carrier is that a less 
regulated pulmonary inflammatory response to an external noxious stimulus (e.g. infection) 
would lead to higher chances of recovery. Prior to the discovery of antibiotics for respiratory 
infections, the mortality rate from these illnesses was high. A more robust and unregulated 
inflammatory response in the lungs could have provided a survival advantage to the 
carriers (Lomas, 2006). In the modern antibiotic era, and the advent of mass-produced 
external noxious stimuli (smoking, pollution), this mutation does not appear to have a 
theoretical selective advantage anymore. 
How cigarette smoke accelerates the decline of lung function in A1ATD has also been 
studied. When the methionine amino acid in the active site of A1AT protein is oxidized by 
cigarette smoke, the kinetics of neutrophil elastase inhibition is reduced (Ogushi et al., 1991). 
Newer experimental data shows A1AT may have other roles in the lung epithelium besides 
inhibiting neutrophil elastase. A1AT has recently been found to block the cigarette smoke 
mediated release of TNF-alpha and MMP-12 in alveolar macrophages (Churg at al., 2007). In 
cellular studies, A1AT has also been found to inhibit apoptosis through direct inhibition of 
activated Caspase-3 (Petrache et al., 2006). The link between A1AT and apoptosis has lead to 
new theories of emphysema development as both an inflammatory disorder and accelerated 
lung aging process.  
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5.2 Liver pathophysiology 
People with the alpha one antitrypsin deficiency develop liver damage by a completely 
different mechanism. After being synthesized in hepatocytes, the mutated A1AT alleles bind 
together to form large polymers that result in inflammation and fibrosis. Liver disease 
caused by A1ATD has become the prototypical disease in a new category of diseases, 
termed the conformational diseases. Also included in this category of diseases are 
Alzheimer's and other forms of neurodegenerative dementias, which are caused by the 
aggregation of proteins in neurons (Carrell & Lomas, 2002). People with the PI*ZZ mutation 
of A1AT have a high concentration of the mutated alpha-one antitrypsin allele in the 
endoplasmic reticulum of liver cells. The Z mutation allows the protein to undergo a 
spontaneous structural change, which opens up the main sheets of the molecule and bind to 
the reactive center in the next molecule. These interactions can result in the formation of 
long polymers of mutated proteins (Lomas et al., 1992). The large protein structures 
aggregate in liver cells, which is thought to lead to inflammation, fibrosis and cirrhosis by a 
still unclear mechanism. The reason why some people with ZZ allele genotype do not 
develop clinically relevant liver disease is also not clear. 
6. Clinical manifestations 
A1ATD is often unrecognized despite the high prevalence of lung disease in the United 
States and the world. Alpha-1–related lung disease presents with common respiratory 
symptoms including dyspnea, decreased exercise tolerance, wheezing, cough, excess 
sputum production, frequent lower respiratory tract infections, and a history of suspected 
allergies and/or asthma (Needham & Stockley, 2004). These symptoms are often ascribed to 
other diseases for years prior to the correct diagnosis of alpha one antitrypsin deficiency. A 
1994 mail survey found that on average it took 7.2 years after symptom onset before the 
diagnosis was made, and 44% of people saw three different physicians before a diagnosis 
was made (Stoller et al., 1994). A similar survey repeated in 2003 found the mean time to 
diagnosis was 5.6 years, however, the delay was more pronounced in older and female 
patients (Stoller et al., 2005).  Since the diagnosis of A1ATD requires one simple blood test, 
clearly more effort needs to be made to educate both physicians and the public of the 
disease and the importance of a diagnosis.  
There is significant variability in the age of symptom onset in people with A1ATD, and 
some smokers and non-smokers may never develop symptoms. This highlights the 
variability in disease penetrance among deficient individuals, and makes accurate 
descriptions of the common symptoms and other clinical characteristics of deficient 
individuals difficult to obtain. Most of the clinical characteristics and other features of the 
deficiency are obtained by studying large registries of patients with the disease. These data 
sets are often flawed by ascertainment bias. Most of the patients in the large A1ATD 
registries presented initially to a doctor with concerning pulmonary symptoms, eventually 
leading to a diagnosis of A1ATD. These patients are then referred to a specialist who will 
enroll them into the registry, and are termed index cases. Less often, asymptomatic 
individuals who are diagnosed after a family screening are enrolled (non-index cases). This 
was true of the large group of 1129 A1AT deficient individuals in the National Heart, Lung 
and Blood Institute Registry (McElvaney et al., 1997). 72% of the enrollees were index cases, 
receiving a diagnosis of the A1ATD after developing concerning pulmonary symptoms, and 
20% were non-index cases, diagnosed by screening following an investigation of family 
members of individuals with A1ATD. In that registry, the remaining smaller percentage of 
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people were diagnosed after they were discovered to have abnormal chest radiograph 
findings, abnormal pulmonary function tests, liver abnormalities, or other blood testing. 
therapy with the purified A1AT protein. 
6.1 Pulmonary clinical manifestations 
The NHLBI registry data provides the best clinical picture of the typical patients diagnosed 
with this deficiency. 97% of them had the PI*ZZ mutation, and most were diagnosed in the 
third or fourth decade of life. The most common symptom in this group was shortness of 
breath on exertion (83%). Other common symptoms included wheezing during an upper 
respiratory illness (75%), wheezing without upper respiratory illness (65%), recent lung 
infection (67%), and chronic productive cough (49%).  
Pulmonary function testing of individuals in the NHLBI registry demonstrated a pattern 
consistent with emphysema: the median Forced Expiratory Volume in one second (FEV1) 
was 47% of predicted, the ratio of the FEV1/FVC (Forced Vital Capacity) was 43% of 
predicted, and the DLCO (which represents the amount of destruction in alveoli-capillary 
units) was 50% of predicted. These numbers highlight a common feature of people with 
A1ATD: the airflow obstruction (represented by low FEV1 and low FEV1/FVC) seen on 
pulmonary function testing seems to be out of proportion to the lifetime quantity of 
cigarettes they have smoked. Also in the NHLBI registry, 28% of people showed significant 
bronchodilator responsiveness (i.e., reversibility) of their airflow obstruction on pulmonary 
function tests during their initial visit, which is a characteristic of people with asthma (Eden 
et al., 2003). With these common symptoms and pulmonary function test characteristics, it is 
easy to see why patients with A1ATD are often misdiagnosed as having only uncomplicated 
asthma, emphysema or COPD. 
In contrast to the above registry data, a study with high level of non-index cases (e.g. 
siblings of affected individuals) found that far fewer of this population had typical 
pulmonary symptoms of A1ATD (Seersholm & Kok-Jensen, 1998). After a mean follow-up 
of 8 years, only 46% of the non-index case patients reported symptoms of shortness of 
breath, 27% reported wheezing, and 14% reported a chronic cough. Also in this group, their 
average FEV1 was 100% of predicted, and their FEV1/FVC = 0.79, essentially normal 
pulmonary function tests. 
Classically, severe A1ATD causes panlobar emphysema with lower lobe predominance on 
radiologic imagining studies (Guenter et al., 1968). However, with high-resolution chest CT 
scanning, bronchiectasis has also been found to be a common feature of patients with 
A1ATD. In a study of 74 people with the P*ZZ phenotype, 70 subjects had bronchiectasis 
changes on CT scan. 27% of the study participates were felt to have clinically significant 
bronchiectasis, which was described as 4 or more airway segments with bronchiectasis plus 
symptoms of regular sputum production (the most common symptom of people with 
bronchiectasis) (Parr et al., 2007). 
Multiple studies have measured the rate of decline in lung function among patients with 
A1ATD using the forced expiratory volume in one second (FEV1) as a marker of lung 
disease progression. This measure is used regularly to quantify the severity and progression 
of patients with COPD and asthma. For non-smokers with normal levels of A1AT, the rate 
of FEV1 decline is around 20-30 mL/year. The decline in the FEV1 among a group of 
A1ATD patients who never smoked was 67 mL/year, was 54 mL/year in ex-smokers, and 
was 109 mL/year in current smokers (Alpha-1-antitrypsin deficiency study group, 1998). 
The first two numbers are not statistically significantly different, however the third is 
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significant, which highlights the extreme importance of smoking cessation in all people with 
A1ATD. The difference in the rate of decline of FEV1 between A1ATD and normal patients 
highlights the principle of augmentation therapy with replacement alpha-one protein. 
Mortality in people with A1ATD is most frequently due to respiratory failure, followed by 
liver cirrhosis. The observed yearly mortality rate ranges between 1.7-3.5%. Factors 
associated with increased mortality include older age, lower education, lower FEV1, history 
of lung transplant, and people who were not receiving augmentation therapy with the 
purified A1AT protein (Stoller et al., 2005). 
6.2 Liver clinical manifestations 
A1ATD has a strong association with liver disease, leading to a recommendation that all 
individuals of any age with unexplained liver dysfunction should undergo testing for the 
deficiency. In the Swedish population screening study by Sveger, of 200,000 people, 18% of 
the 120 people found to be homozygote for the Z mutation had some evidence of liver 
dysfunction (Sveger, 1974). This included obstructive jaundice in 12%, and minor 
abnormalities in others. Among those with liver dysfunction, the risk of developing cirrhosis is 
high. It is possible that younger individuals more often have liver dysfunction because their 
hepatocytes are less well equipped to handle the polymerized A1AT proteins. In a small 
autopsy series of patients with A1AT disease, cirrhosis was observed in 34% of patients, and 
hepatocellular carcinoma was observed in 34% of those with cirrhosis (Eriksson, 1987). 
6.3 Necrotizing panniculitis 
Panniculitis is an uncommon skin disorder with a strong association with A1ATD. It is 
characterized by painful, cutaneous nodules at the sites of trauma, often on the trunk, back 
and thighs. On biopsy, areas of fat necrosis are interspersed with areas of normal tissue. The 
skin necrosis is felt to develop because of unopposed proteolysis, and augmentation therapy 
has been described as causing a rapid resolution of the disease (Dowd et al., 1995).  
7. Testing for disease 
Guidelines published by the American Thoracic Society and European Respiratory Society 
in 2003 have helped clarify who should undergo testing for A1ATD (American Thoracic 
Society, 2003). The guidelines divided people into categories for whom testing is 
recommended, those for whom testing could be discussed and considered, and those for 
whom testing was discouraged. For the following group of people testing should be 
recommended. These include: adults with emphysema, chronic obstructive pulmonary 
disease, or asthma with incompletely reversible airflow obstruction, people of all ages with 
otherwise unexplained liver disease, or adults with necrotizing panniculitis. In the following 
group of people testing could be considered and discussed: adults with bronchiectasis 
without an obvious etiology, adults with anti-proteinase 3-positive vasculitis (C-ANCA 
[anti-neutrophil cytoplasmic antibody]-positive vasculitis, formerly known as “Wegener’s 
Granulomatosis”), adolescents with airflow obstruction on pulmonary function tests. 
When family history is considered, the following recommendations were made. There is a 
strong recommendation for testing all siblings of an individual with A1ATD. There is also a 
recommendation to consider testing in the following situations: individuals with a family 
history of emphysema or liver disease, or anyone with a family history of A1ATD or A1ATD 
heterozygote. The 2003 guidelines recommended against routine population screening except 
www.intechopen.com
 
Alpha One Antitrypsin Deficiency: A Pulmonary Genetic Disorder 235 
in the following circumstances - if the prevalence of A1ATD is greater than 1 in 1500 the 
population, smoking is prevalent, and adequate genetics counseling services are available.  
Nephelometry or Rocket Immunodiffusion can measure serum levels of A1AT and is a 
reasonable screening test for the deficiency. However, this method is subject to errors 
because the protein is an acute phase reactant and rise with inflammation. The gold 
standard for diagnosis is “Phenotyping” of the protein is done via isoelectric focus gel 
analysis, which can only be performed at a few specialized laboratories within the United 
States. DNA Analysis of genotype is done to probe for the common S and Z genes. A1ATD 
testing can be done via serum and whole blood draw from the vein, but can also be done via 
a single finger-stick of blood placed onto a card that is mailed into a central lab for testing. A 
combination of measuring the serum A1AT concentration and performing a PCR based 
assay to identify S and Z alleles will accurately identify 96% of individuals as compared to 
the more difficult gold standard isoelectric focusing (Snyder, 2006).  
8. Treatment 
The corner stone of alpha one antitrypsin management is smoking cessation and smoke 
avoidance in all individuals with the deficiency. Guidelines for the management of the 
chronic airflow obstruction (COPD) have been published elsewhere (GOLD guidelines, ATS 
guidelines, etc.)  Augmentation therapy is utilized to increase serum and lung epithelial 
lining fluid (ELF) levels of A1AT through the weekly intravenous infusion of purified 
human A1AT protein (Wewers et al., 1987). 
It is FDA approved to treat for adult patients with A1ATD (protein concentration < 11 
micromoles/dL) and evidence of air flow obstruction. The treatment can be very costly 
because it involves life-long regular infusions of a blood product, and it is not available 
worldwide. The treatment was approved based on two factors, that there is biochemical 
equivalence between exogenous replacement protein and protein found in normal human 
serum, and there is normalization of serum protein levels in deficient individuals who are 
receiving replacement. Many non-randomized prospective studies have demonstrated the 
effectiveness of augmentation via reduction in the annual rate of decline of lung function. 
Well-designed and adequately powered randomized trials have been limited to date. A 
recent meta-analysis of published human studies demonstrated augmentation therapy does 
reduce the annual rate of lung function decline (as measured by FEV1) in A1ATD 
individuals (Chapman et al., 2009). 
8.1 Future therapies 
Ongoing work in areas of inhaled therapy, longer half-life protein, recombinant forms, small 
molecule chaperone inhibitors to increase liver secretion and gene transfer therapy continue. 
These studies and fields are all in various stages of development.  
9. Conclusion 
Alpha1- antitrypsin deficiency is a not uncommon disease, which is not limited to the 
European and Caucasian American population, but now affects all ethnic groups. Effective 
treatments for this disease, including smoking cessation, management of 
COPD/emphysema and other complications, and augmentation therapy with purified 
A1AT protein is well established. However, the disease remains under-diagnosed, and 
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many times patients are diagnosed years after symptoms have developed. Future work to 
improve education among healthcare professionals to improve rates of diagnosis, as well as 
improved disease specific treatments are important steps in making this disease a more 
treatable illness. 
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